NSE filing, NSE: MEDPLUS. Summary written from the filing by ALFA Finder's alert engine.
Medplus Health Services Ltd: key numbers
- Share price
- ₹609.40
- Market cap
- ₹7,321 Cr
- Revenue (annual)
- ₹6,892 Cr
- Net profit (annual)
- ₹219.7 Cr
- P/E (TTM)
- 34.7×Sector 52.0×
- Promoter holding
- 40.19%+0.00% QoQ
- FII holding
- 12.58%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Medplus Health Services Ltd
All →Medplus Health Services Earnings Call Transcript: Key Takeaways
Medplus reported Q2 revenue of ₹2,037.1 Cr with 21.3% pharmacy growth, but EBITDA margins were hit by state-mandated wage hikes.
- Call
- Guides 10% growth
Medplus Health Services Share Pledge
Catalyst Trusteeship pledged 34,00,000 Medplus Health Services shares (2.83%) as debenture collateral. Total encumbered shares rose to 2,41,50,400 (20.10% of capital).
Medplus Health Services Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹2,037cr (+21.3% YoY), operating EBITDA ₹98cr (4.8% margin), reported PAT ₹56cr (+1% YoY). Store expansion continues; no explicit guidance given.
Medplus Health Services Q2 FY27 Results: Net Profit ₹56.1 Cr, Up 1.1% YoY
Medplus Health Services Ltd reported revenue from operations of ₹2,037 Cr (+21.3% YoY) and net profit of ₹56.1 Cr (+1.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹56.1 Cr · +1.1% YoY
Medplus Health Services Adverse Business Impact
Optival Health, a MedPlus subsidiary, had drug licences suspended at five Karnataka stores for 1–7 days. Expected impact is about Rs 8.66 lakhs.
- Value
- ₹0.09 Cr
- Execution
- 1 to 7 days per store
Medplus Health Services Adverse Business Impact
Medplus Health Services' subsidiary Optival Health faced temporary drug license suspensions for two stores by Mysore regulators. The estimated operational impact is ₹0.02 Crore.
- Value
- ₹0.02 Cr
Other employee stock options announcements
All →RateGain Travel Technologies Employee Stock Options
RateGain granted 53,021 Stock Appreciation Rights under its SAR Scheme 2022 at ₹800 and ₹862.25 per unit. The grants vest over four years and are exercisable within three years of vesting.
- Execution
- Vesting over 4 years (10% Y1, 20% Y2, 30% Y3, 40% Y4); exercisable within 3 years of vesting
Aye Finance Employee Stock Options
Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
OnEMI Technology Solutions Employee Stock Options
OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bandhan Bank Employee Stock Options
Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.